Klaus-Michael Debatin

Professor of Pediatrics

Universität Ulm

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Klaus-Michael Debatin is a faculty member in the Department of Pediatrics at Universität Ulm, Germany. His research focuses on hematological malignancies, immunology, and therapeutic approaches in pediatric oncology, as evidenced by his recent publications on leukemia, immune response to SARS-CoV-2, and mechanisms of drug resistance. He is particularly interested in the interactions between leukemia cells and their microenvironment, as well as the role of myeloid-derived suppressor cells in cancer biology.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (6)

Georg C. Schwabe

Medical University Lausitz - Carl Thiem

GERMANY

View details

Felix Seyfried

University Hospital Ulm

GERMANY

View details

Bjoern Traenkle

institute of biochemistry university of tübingen tübingen germany

GERMANY

View details

Catharina Schütz

Academic Staff, full professor

TUD Dresden University of Technology

GERMANY

View details

Florian Zeman

Head Biometrician / Vice Head

University Hospital Regensburg

GERMANY

View details

Ulrich Pannicke

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Klaus-Michael Debatin

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Bridging the marrow: a co-culture-platform of leukemia cells and MS5-derived stromal cells or adipocytes.

Aging modulates the immunosuppressive, polarizing and metabolic functions of blood-derived myeloid-derived suppressor cells (MDSCs).

Longitudinal analysis of humoral and cellular immunity in SARS-CoV-2 exposed families.

RAG recombinase expression discriminates the development of natural killer cells.

Remission induction in refractory, drug resistant pediatric PICALM::MLLT10+ B-cell acute lymphoblastic leukemia by venetoclax.

Venetoclax resistance in acute lymphoblastic leukemia is characterized by increased mitochondrial activity and can be overcome by co-targeting oxidative phosphorylation

Non-Skewed X-inactivation Results in NF-κB Essential Modulator (NEMO) Δ-exon 5-autoinflammatory Syndrome (NEMO-NDAS) in a Female with Incontinentia Pigmenti

The dual BCL-2 and BCL-XL inhibitor AZD4320 acts on-target and synergizes with MCL-1 inhibition in B-cell precursor ALL

Benchmarking miRNA reference genes in B-cell precursor acute lymphoblastic leukemia.

Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.

Collaborators (6)

Georg C. Schwabe

Felix Seyfried

Bjoern Traenkle

Catharina Schütz

Florian Zeman

Ulrich Pannicke

Make your next move.